The Lancet Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
24(7), P. e453 - e462
Published: Feb. 7, 2024
SARS-CoV-2
causes
persistent
infections
in
a
subset
of
individuals,
which
is
major
clinical
and
public
health
problem
that
should
be
prioritised
for
further
investigation
several
reasons.
First,
infection
often
goes
unrecognised,
therefore
might
affect
substantial
number
people,
particularly
immunocompromised
individuals.
Second,
the
formation
tissue
reservoirs
(including
non-respiratory
tissues)
underlie
pathophysiology
require
new
strategies
diagnosis
treatment.
Finally,
replication,
setting
suboptimal
immune
responses,
possible
source
new,
divergent
virus
variants
escape
pre-existing
immunity
on
individual
population
levels.
Defining
optimal
diagnostic
treatment
patients
with
replication
monitoring
viral
evolution
are
urgent
medical
priorities.
Infection,
Journal Year:
2023,
Volume and Issue:
52(3), P. 877 - 889
Published: Nov. 29, 2023
Prolonged
shedding
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
has
been
observed
in
immunocompromised
hosts.
Early
monotherapy
with
direct-acting
antivirals
or
monoclonal
antibodies,
as
recommended
by
the
international
guidelines,
does
not
prevent
this
certainty.
Dual
therapies
may
therefore
have
a
synergistic
effect.
Frontiers in Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: Feb. 29, 2024
Objectives
The
aim
of
the
study
was
to
describe
a
cohort
B-cell-depleted
immunocompromised
(IC)
patients
with
prolonged
or
relapsing
COVID-19
treated
monotherapy
combination
therapy.
Methods
This
is
multicenter
observational
retrospective
conducted
on
IC
consecutively
hospitalized
SARS-CoV-2
infection
from
November
2020
January
2023.
subjects
were
stratified
according
anti-SARS-CoV-2
therapy
received.
Results
Eighty-eight
enrolled,
19
under
and
69
population
had
history
immunosuppression
(median
2
B-cells/mm
3
,
IQR
1–24
cells),
residual
hypogammaglobulinemia
observed
in
55
patients.
A
reduced
length
hospitalization
time
negative
molecular
nasopharyngeal
swab
(NPS)
versus
group
observed.
In
univariable
multivariable
analyses,
percentage
change
rate
days
NPS
negativity
showed
significant
reduction
receiving
compared
those
monotherapy.
Conclusion
persistent
patients,
it
essential
explore
new
therapeutic
strategies
such
as
multi-target
(antiviral
double
antiviral
plus
antibody-based
therapies)
avoid
viral
shedding
and/or
severe
infection.
International Journal of Antimicrobial Agents,
Journal Year:
2024,
Volume and Issue:
63(3), P. 107095 - 107095
Published: Jan. 21, 2024
Antivirals
and
monoclonal
antibodies
are
available
to
lower
progression
risk
in
immunocompromised
patients.
However,
combination
therapy
with
both
types
of
agents
has
not
been
studied.
Single-centre
prospective
cohort
study.
We
enrolled
all
patients
who
received
treatment
for
mild-to-moderate
COVID-19
from
January
1st,
2022,
October
30th,
2022.
Primary
endpoint
was
at
90
days,
defined
as
hospital
admission
or
death
due
and/or
seronegative
persistent
Three
hundred
four
(304)
were
included.
43
(14.1%)
sotrovimab
plus
a
direct-acting
antiviral
261
(85.9%)
monotherapy.
outcome
occurred
more
frequently
after
monotherapy
(4.6%
vs
0%,
p=0.154).
Among
anti-Spike
IgG
titter
below
750
BAU/mL,
frequent
(23.9%
p=0.001),
including
COVID-related
(15.2%
p=0.014)
(10.9%
p=0.044).
Combination
associated
(OR
0.08,
95%
CI
0.01-0.64).
Anti-S
than
BAU/mL
previous
antiCD20
higher
13.70,
2.77-67.68;
OR
3.05,
1.20-10.94,
respectively).
In
immunocompromised,
an
may
be
effective
SARS-CoV2.
International Journal of Infectious Diseases,
Journal Year:
2023,
Volume and Issue:
137, P. 55 - 59
Published: Sept. 30, 2023
After
the
third
year
of
COVID-19
pandemic,
most
severe
burden
falls
upon
immunocompromised
patients
who
cannot
mount
an
endogenous
immune
response
after
both
vaccination
and/or
natural
infection.
They
also
experience
persistent
SARS-CoV-2
infection
with
high
viral
loads
often
unsuccessfully
managed
by
standard
antiviral
monotherapy
regimen
initially
validated
for
treatment
immunocompetent
patients,
only.
The
off-label
prescription
such
regimens
in
is
likely
to
drive
emergence
treatment-related
escape,
relapses,
excess
morbidity,
and
mortality
from
delayed
underlying
disorders.
A
possible
approach
mitigate
consequence
based
on
combined
therapies.
Virology Journal,
Journal Year:
2023,
Volume and Issue:
20(1)
Published: Dec. 15, 2023
Abstract
Background
Morbidity
and
mortality
are
higher
in
immunocompromised
patients
affected
by
COVID-19
than
the
general
population.
Some
authors
have
successfully
used
antiviral
combination,
but
never
early
phase
of
infection.
Methods
We
conducted
a
retrospective
cohort
study
to
determine
efficacy
safety
combination
two
antivirals,
with
without
monoclonal
antibody
(mAb),
both
(within
10
days
symptoms)
later
(after
days)
SARS-CoV-2
infection
admitted
our
Facility.
Results
treated
11
(seven
an
four
late
COVID-19)
intravenous
remdesivir
plus
five
oral
nirmatelvir/ritonavir,
also
combined
sotrovimab
10/11
cases.
Notably,
all
“early”
reached
virological
clearance
at
day
30
from
end
therapy
were
alive
well
follow-up,
whereas
corresponding
numbers
“late”
50%
75%.
Patients
group
more
frequently
needed
oxygen
supplementation
(p
=
0.015)
steroid
0.045)
during
admission
severity
0.017).
Discussion
The
is
tolerated
associated
100%
clearance.
lower
response
rates
disease
severity,
whether
plays
causative
role
such
findings
has
yet
be
determined.
